X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
glucagon (38) 38
humans (38) 38
endocrinology & metabolism (33) 33
diabetes (29) 29
receptors, glucagon - antagonists & inhibitors (29) 29
glucose (26) 26
type 2 diabetes (22) 22
diabetes mellitus, type 2 - drug therapy (21) 21
blood-glucose (18) 18
male (18) 18
glucagon receptor antagonist (17) 17
hyperglycemia (16) 16
insulin (16) 16
animals (15) 15
hypoglycemic agents - therapeutic use (14) 14
dextrose (13) 13
diabetes mellitus (13) 13
female (13) 13
secretion (13) 13
postprandial hyperglycemia (12) 12
adult (11) 11
diabetes mellitus, type 2 - metabolism (11) 11
glucagon - metabolism (11) 11
middle aged (11) 11
glucagon receptor (10) 10
hyperglucagonemia (10) 10
analysis (9) 9
blood glucose - drug effects (9) 9
care and treatment (9) 9
double-blind method (9) 9
insulin - metabolism (9) 9
knockout mice (9) 9
liver (9) 9
mice (9) 9
pharmacodynamics (9) 9
type-2 diabetes-mellitus (9) 9
aged (8) 8
dose-response relationship, drug (8) 8
hypoglycemic agents - adverse effects (8) 8
hypoglycemic agents - pharmacology (8) 8
pharmacokinetics (8) 8
rodents (8) 8
biochemistry & molecular biology (7) 7
chemistry, medicinal (7) 7
hypoglycemic agents - administration & dosage (7) 7
insulin resistance (7) 7
liver - metabolism (7) 7
ly2409021 (7) 7
medicine & public health (7) 7
mellitus (7) 7
pharmacology & pharmacy (7) 7
blood glucose - metabolism (6) 6
diabetes mellitus, type 2 - physiopathology (6) 6
endogenous glucagon (6) 6
fasting (6) 6
glp-1 (6) 6
glucagon - antagonists & inhibitors (6) 6
glucagon-like peptide-1 receptor - agonists (6) 6
glycemic control (6) 6
homeostasis (6) 6
hypoglycemia (6) 6
internal medicine (6) 6
metabolism (6) 6
physiological aspects (6) 6
rats (6) 6
receptor antagonist ly2409021 (6) 6
alpha-cell hyperplasia (5) 5
antagonist ly2409021 (5) 5
beta-alanine - analogs & derivatives (5) 5
chemistry, organic (5) 5
diabetes mellitus, type 2 - blood (5) 5
hypoglycemia - chemically induced (5) 5
hypoglycemic agents (5) 5
hypoglycemic agents - pharmacokinetics (5) 5
molecular structure (5) 5
obesity (5) 5
obesity - drug therapy (5) 5
receptors, glucagon - metabolism (5) 5
safety (5) 5
signal transduction - drug effects (5) 5
young adult (5) 5
antagonist (4) 4
antibodies, monoclonal - adverse effects (4) 4
beta-cell function (4) 4
biphenyl compounds - therapeutic use (4) 4
blood sugar (4) 4
discovery (4) 4
endocrine system (4) 4
glucagon - secretion (4) 4
glucagon antagonist (4) 4
gluconeogenesis (4) 4
glucose homeostasis (4) 4
glucose-production (4) 4
glycosylated hemoglobin (4) 4
health aspects (4) 4
hormones, hormone substitutes, and hormone antagonists (4) 4
hyperglycemia - drug therapy (4) 4
hyperglycemia - prevention & control (4) 4
hyperplasia (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2015, Volume 17, Issue 4, pp. 414 - 422
Aim: To describe the clinical effects of single and multiple doses of a potent, selective, orally administered, small-molecule antagonist of the human glucagon... 
pharmacokinetics | diabetes care | glucagon antagonist | pharmacology | Pharmacology | Glucagon antagonist | Pharmacokinetics | Diabetes care | HYPERGLUCAGONEMIA | MELLITUS | KNOCKOUT MICE | INSULIN | OBESITY | GLUCONEOGENESIS | ALPHA CELL HYPERPLASIA | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | PLASMA-GLUCOSE | Glycated Hemoglobin A - analysis | Single-Blind Method | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Humans | Middle Aged | Half-Life | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Biphenyl Compounds - therapeutic use | Glucagon - blood | Glucagon - agonists | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Hypoglycemic Agents - blood | Hypoglycemic Agents - administration & dosage | Adult | Female | Biphenyl Compounds - blood | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biphenyl Compounds - pharmacokinetics | Hypoglycemic Agents - pharmacokinetics | Molecular Targeted Therapy - adverse effects | Double-Blind Method | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Biphenyl Compounds - administration & dosage | Aged | Glucagon - secretion | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Type 2 diabetes | Glucagon | Blood sugar | Low density lipoproteins | Fasting | Diabetes | Glucose | Index Medicus
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2017, Volume 19, Issue 8, pp. 1071 - 1077
Aims: To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes. Materials and methods: This 6-week, randomized,... 
clinical trial | glucagon receptor antagonist | type 2 diabetes | TRIAL | PHARMACOKINETICS | CIRCULATION | SAFETY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | PHARMACODYNAMICS | MELLITUS | Glycated Hemoglobin A - analysis | Receptors, Glucagon - antagonists & inhibitors | Follow-Up Studies | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Biphenyl Compounds - therapeutic use | Hypoglycemia - prevention & control | Hypoglycemic Agents - administration & dosage | Hypertension - chemically induced | Female | Blood Pressure - drug effects | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Hypoglycemic Agents - therapeutic use | Diabetic Angiopathies - chemically induced | Hyperglycemia - prevention & control | Double-Blind Method | Administration, Oral | Biomarkers - blood | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Biphenyl Compounds - administration & dosage | Hypertension - complications | Aged | Blood Pressure Monitoring, Ambulatory | Diabetes Mellitus, Type 2 - drug therapy | Hyperlipidemias - chemically induced | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Glucagon | Glycosylated hemoglobin | Blood pressure | Blood lipids | Glucose | Dextrose | Patients | Diabetes | Index Medicus
Journal Article
DIABETES CARE, ISSN 0149-5992, 04/2019, Volume 42, Issue 4, pp. 585 - 593
OBJECTIVE To evaluate the safety and efficacy of IONIS-GCGR(Rx), a 2 '-O-methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the... 
TARGET | PHARMACOKINETICS | METABOLISM | CHOLESTEROL | REDUCTION | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | PHARMACODYNAMICS | ANTAGONIST LY2409021 | BLOOD-PRESSURE | OLIGONUCLEOTIDES
Journal Article
Medecine des Maladies Metaboliques, ISSN 1957-2557, 02/2018, Volume 12, Issue 1, pp. 16 - 21
Despite numerous studies dating back more than 60 years, showing the key role of glucagon in the pathophysiology of diabetes, especially type 2 diabetes,... 
treatment | insulin | glucagon | Diabetes | LY2409021 | glucagon receptor antagonists
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 03/2017, Volume 114, Issue 10, pp. 2747 - 2752
Genetic disruption or pharmacologic inhibition of glucagon signaling effectively lowers blood glucose but results in compensatory glucagon hypersecretion... 
Glucagon receptor | Angptl4 | Antibody | α-cell mass | ANTIBODIES | antibody | glucagon receptor | IMMUNOGLOBULIN GENES | ANGPTL8/BETATROPHIN | MULTIDISCIPLINARY SCIENCES | BLOOD-GLUCOSE | KNOCKOUT MICE | ANTAGONIST LY2409021 | alpha-cell mass | DISRUPTION | HYPOGLYCEMIA | HUMANIZATION | TYPE-2 DIABETES-MELLITUS | Index Medicus | Biological Sciences
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2018, Volume 20, Issue 11, pp. 2608 - 2616
Aims: To conduct a dose-response assessment of the efficacy and safety of the glucagon receptor antagonist PF-06291874 in adults with type 2 diabetes (T2DM)... 
phase 2 studies | metformin | glucagon receptor | pharmacodynamics | INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | RISK | LY2409021 | SECRETION | Receptors, Glucagon - antagonists & inhibitors | Humans | Middle Aged | Male | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Adult | Female | Blood Pressure - drug effects | Metformin - administration & dosage | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Pyrazoles - adverse effects | beta-Alanine - adverse effects | Double-Blind Method | beta-Alanine - administration & dosage | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Pyrazoles - administration & dosage | Diabetes Mellitus, Type 2 - physiopathology | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Medical research | Care and treatment | Glucagon | Low density lipoproteins | Glycosylated hemoglobin | Bilirubin | Glucose | Dextrose | Medicine, Experimental | Hypoglycemic agents | Dosage and administration | Statins | Diabetes therapy | Lipoproteins (low density) | Alanine | Diabetes mellitus | Liver | Body weight | Lipids | Hypoglycemia | Cholesterol | Hemoglobin | Alanine transaminase | Aspartate aminotransferase | Blood pressure | Diabetes | Metformin | Safety | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 283 - 291
AimsGlucagon receptor (GCGR) blockers are being investigated as potential therapeutics for type 1 and type 2 diabetes. Here we report the safety, tolerability,... 
phase 1 | glucagon stimulation | REGN | 1193 | GCGR | REGN1193 | ALPHA-CELLS | BLOOD-GLUCOSE | PANCREAS | HYPERPLASIA | ANTAGONIST LY2409021 | ISLET-CELL TUMOR | INSULIN | ENDOCRINOLOGY & METABOLISM | MICE | SECRETION | TYPE-2 DIABETES-MELLITUS | Receptors, Glucagon - antagonists & inhibitors | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Antibodies, Blocking - pharmacology | Patient Dropouts | Antibodies, Blocking - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Adult | Female | Antibodies, Blocking - blood | Hypoglycemic Agents - pharmacokinetics | Lost to Follow-Up | Blood Glucose - analysis | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Receptors, Glucagon - metabolism | Biomarkers - blood | Hypoglycemic Agents - pharmacology | Antibodies, Blocking - adverse effects | Antibodies, Monoclonal - administration & dosage | Infusions, Intravenous | Hypoglycemic Agents - adverse effects | Cohort Studies | Type 2 diabetes | Hyperglycemia | Safety and security measures | Glucagon | Analysis | Therapeutics | Monoclonal antibodies | Glucose | Dextrose | Homeopathy | Materia medica and therapeutics | Food | Lipoproteins (low density) | Pharmacodynamics | Diabetes mellitus | Liver | Diabetes mellitus (insulin dependent) | Hypoglycemia | Plasma levels | Safety | Pharmacokinetics | Diabetes mellitus (non-insulin dependent) | Nonlinear systems | Index Medicus | Original
Journal Article
15.